¿Cuáles son las causas, síntomas y tratamiento de la pielonefritis?

Respuesta generada por Itaca · 45 fuentes · 27 de enero de 2026

Pregunta original

pielonefritis, causas, síntomas, y tratamientos

Pyelonephritis: A Comprehensive Clinical Review of Etiology, Manifestations, and Therapeutic Approaches

Pyelonephritis represents a serious infection of the renal parenchyma and pelvic collecting system that constitutes one of the most prevalent infectious diseases affecting the genitourinary system[1][2]. This condition typically originates as a urinary tract infection in the lower urinary tract—specifically the bladder or urethra—and ascends proximally through the ureters to involve one or both kidneys[1][3]. The disease affects multiple demographic populations with varying incidence patterns, demonstrates substantial potential for serious complications including sepsis and chronic renal scarring, and requires prompt diagnosis and targeted antimicrobial therapy to prevent long-term morbilitation. The pathophysiology of pyelonephritis involves complex interactions between bacterial virulence factors, host immune mechanisms, and anatomic factors within the urinary system, all of which influence disease progression and treatment efficacy. When managed appropriately with early antibiotic intervention, acute pyelonephritis generally resolves without permanent sequelae; however, untreated cases, particularly those complicated by urinary obstruction or vesicoureteral reflux, can progress to chronic pyelonephritis characterized by irreversible renal scarring, parenchymal atrophy, and progressive functional impairment[1][4]. This comprehensive review examines the multifaceted aspects of pyelonephritis including its definition and classification, epidemiological distribution across populations, etiopathogenic mechanisms, clinical diagnostic algorithms, microbiological considerations with emphasis on antimicrobial resistance, management strategies stratified by disease severity and patient characteristics, preventive measures, and complications warranting clinical vigilance.

Definition, Classification, and Pathophysiologic Foundations

Pyelonephritis is formally defined as a bacterial infection of the renal parenchyma, collecting ducts, and caliceal system that represents the upper urinary tract infection in contrast to lower urinary tract infections such as cystitis or uretritis[1][5]. The disease typically manifests acutely with characteristic clinical features including fever, costovertebral angle tenderness, flank pain, and constitutional symptoms accompanied by significant bacteriuria, distinguishing it pathophysiologically from the lower tract involvement seen in simple cystitis[1]. From a nosological perspective, pyelonephritis exists along a continuum as either acute pyelonephritis, representing a single or recurrent acute inflammatory episode with intact parenchymal architecture, or chronic pyelonephritis, characterized by persistent or recurrent infection with development of cortical and medullary scarring, caliceal atrophy, and progressive renal fibrosis[1][6]. The distinction between these forms carries substantial prognostic implications, as acute pyelonephritis when appropriately treated typically resolves completely without permanent structural sequelae, whereas chronic pyelonephritis reflects established parenchymal damage and predisposes to progressive loss of renal function[1][4][6].

The classification of pyelonephritis from a clinical management perspective further divides cases into uncomplicated and complicated subtypes based on the presence or absence of underlying urological abnormalities or systemic factors influencing therapeutic approach[1][7]. Uncomplicated pyelonephritis occurs in patients without anatomic or functional disturbances of the urinary system, normal parenchymal architecture, and generally normal host immune function. Conversely, complicated pyelonephritis develops in the context of structural abnormalities such as renal calculi, ureteral strictures, vesicoureteral reflux, urinary obstruction, renal cysts, neurogenic bladder, or in patients with systemic conditions including diabetes mellitus, immunosuppression, or pregnancy that alter the natural history and treatment requirements[1][7]. This distinction fundamentally shapes treatment decision-making, as uncomplicated cases in otherwise healthy individuals may be managed with carefully selected oral antibiotics in ambulatory settings in select cases, while complicated pyelonephritis frequently necessitates hospitalization and intravenous antimicrobial therapy[8][9].

Epidemiological Distribution and Demographics

Pyelonephritis represents one of the most common infectious diseases affecting humans, with global epidemiological estimates suggesting approximately 150 million urinary tract infections are diagnosed annually worldwide, with pyelonephritis comprising a significant proportion of infections requiring hospitalization[10][11]. The disease demonstrates striking gender-related epidemiological patterns, overwhelmingly affecting women across most age groups with particular concentration in sexually active young females and postmenopausal women[5][12][13]. The female predominance reflects multiple anatomic and physiologic factors including the substantially shorter female urethra compared to males, reduced distance between the urethral meatus and the anus facilitating bacterial translocation, hormonal influences on uroepithelial defense mechanisms, and increased frequency of sexual intercourse as a precipitating factor[1][13].

In the pediatric population, pyelonephritis exhibits distinct epidemiological characteristics with bimodal age distribution demonstrating peaks in infants under 90 days of age and in preschool-aged children between three and four years[14][15]. Infants younger than two months with fever lacking apparent focus represent a particularly high-risk group with urinary tract infection prevalence ranging from 2 to 20 percent depending on demographic factors, making investigation for pyelonephritis mandatory in this age stratum[14]. The relative proportion of male to female involvement in pediatric populations differs dramatically from adults, with males comprising approximately 1.5 times the proportion of cases in neonates but thereafter females predominating with increasing age, reaching ratios of 1 female to 10 males in pre-school populations and 1 female to 30 males in school-age children[4]. In elderly populations, the female predominance diminishes substantially as benign prostatic hyperplasia increasingly affects males aged 50 and above, causing urinary retention and increasing infection risk; additionally, age-related physiologic changes in both genders including reduced immune competence, decreased uroepithelial adherence mechanisms, and increased prevalence of systemic comorbidities elevate infection risk[16][17].

Within the population of nonhospitalized individuals, Escherichia coli remains responsible for approximately 80 to 90 percent of community-acquired pyelonephritis cases[18][19][46], whereas nosocomial infections within healthcare settings demonstrate substantially different microbiological patterns with Klebsiella, Enterobacter, Serratia, and Pseudomonas aeruginosa comprising increasingly common pathogens reflecting antibiotic selective pressure in hospital environments[18][14].

Microbiological Etiology and Pathogenic Mechanisms

The microbial etiology of pyelonephritis demonstrates predictable patterns reflecting both the source ecosystem from which uropathogens emanate and the selective environment imposed by the urinary system and host defenses. Escherichia coli, a gram-negative bacillus constituting normal intestinal microbiota, accounts for the predominant causative organism in the vast majority of uncomplicated community-acquired pyelonephritis cases, achieving responsibility for 80 percent of acute episodes in patients lacking preceding urological pathology[18][20][46]. This organism possesses multiple virulence factors facilitating pathogenesis including adhesin molecules such as P fimbriae (pili) that enable binding to uroepithelial cell receptors on the urinary collecting system, hemolysin production contributing to tissue invasion, and flagellar structures promoting bacterial motility within the urinary tract[14][13]. The dominance of E. coli as the etiologic agent reflects both the accessibility of this organism as a component of normal fecal microbiota proximate to urethral and perineal tissues and the organism's possession of particularly robust virulence factors optimized for uroepithelial colonization and ascension.

Alternative pathogenic organisms responsible for the remaining 20 percent of community-acquired cases include diverse gram-negative enteric bacteria from the Enterobacteriaceae family such as Proteus mirabilis, Klebsiella pneumoniae, Enterobacter cloacae, Citrobacter species, and Serratia marcescens[18][14][20]. Among gram-positive organisms, Enterococcus faecalis occasionally causes pyelonephritis particularly in specific clinical contexts such as neonatal infections, nosocomial settings, or following urological interventions, whereas Staphylococcus aureus and Staphylococcus epidermidis remain uncommon in primary pyelonephritis but may emerge in complicated cases involving implanted urological devices[18][20]. In hospitalized patients and those with indwelling catheters, the microbial spectrum shifts substantially toward multidrug-resistant gram-negative bacilli with heightened prevalence of Pseudomonas aeruginosa, extended-spectrum beta-lactamase-producing organisms, and carbapenem-resistant species conferring substantial treatment challenges[14][21].

The pathophysiology of pyelonephritis involves bacterial ascension through the urinary tract, typically originating from colonization of the perineal region and lower urinary tract with subsequent ascent via the urethra and bladder to achieve access to the upper urinary system[16][14]. Under physiologic conditions, the normal unidirectional flow of urine downward from kidneys through ureters provides mechanical clearance preventing bacterial ascension, whereas multiple mucosal and systemic host defense mechanisms including secretory immunoglobulin A, lysozyme, Tamm-Horsfall proteins that trap bacteria, and cellular immunity mechanisms further prevent infection establishment[14]. When these natural defenses become compromised through mechanical obstruction, vesicoureteral reflux allowing retrograde urine flow, or host immune dysfunction, uropathogens successfully colonize the collecting system and parenchyma establishing infection. The resulting inflammatory cascade triggered through Toll-like receptor activation generates local cytokine production including interleukin-8 attracting neutrophils and interleukin-6 activating systemic acute phase response, producing the characteristic fever and systemic symptoms of pyelonephritis[14][58].

Clinical Presentation and Diagnostic Evaluation

The clinical presentation of acute pyelonephritis characteristically manifests with sudden symptom onset featuring the classic triad of fever, flank or costovertebral angle pain, and constitutional malaise, accompanied variably by nausea, vomiting, and chills[1][16][22][13]. The fever in pyelonephritis typically reaches substantial elevations and may present with associated rigors reflecting the systemic inflammatory response to bacterial invasion of renal tissue. The flank pain or costovertebral angle tenderness representing renal parenchymal involvement distinguishes pyelonephritis from simple lower tract cystitis, typically manifesting unilaterally though bilateral kidney involvement can occur in more severe cases[1][16][22]. Approximately one-third of patients with acute pyelonephritis also manifest concurrent lower urinary tract symptoms including dysuria, frequency, urgency, and tenesmo reflecting the frequent simultaneous involvement of bladder tissue in the infection spectrum[16][19].

The clinical presentation demonstrates substantial age-related variability that fundamentally impacts diagnostic recognition and therapeutic urgency. Infants and young children frequently present with nonspecific symptoms such as fever without localizing findings, irritability, lethargy, feeding refusal, or vomiting without the characteristic focal symptoms observed in adolescents and adults, necessitating higher clinical suspicion for pyelonephritis in febrile infants lacking evident alternative explanations for fever[14][15]. Elderly patients present a particularly diagnostic challenge, as infections in this population frequently manifest with atypical presentations lacking fever or localized flank pain, instead presenting with delirium, confusion, altered mental status, falls, or functional decline that may be initially attributed to noninfectious causes[16][17]. This atypical presentation in geriatric populations creates substantial diagnostic delays with potential for disease progression to sepsis and multiorgan failure before appropriate recognition and treatment.

The diagnostic approach to suspected pyelonephritis relies upon integration of clinical history, physical examination findings, and laboratory/imaging studies to establish diagnosis and inform treatment selection. The clinical history should systematically investigate for fever duration, severity and character of flank or costovertebral pain, presence of lower urinary tract symptoms, nausea, vomiting, and risk factors including diabetes, immunosuppression, recent urological instrumentation, pregnancy status, and prior episodes of urinary tract infection[23][7]. Physical examination should include careful assessment of costovertebral angle tenderness via percussion or gentle palpation over the renal angle, assessment for systemic toxicity including hemodynamic instability or evidence of sepsis, and in males over age 50 digital rectal examination to assess for prostate enlargement potentially contributing to urinary obstruction[23][7]. Laboratory evaluation represents a cornerstone of diagnostic confirmation including urinalysis and urine culture, blood culture when fever and systemic toxicity suggest bacteremia risk, and assessment of renal function and systemic inflammatory markers.

The urinalysis provides multiple diagnostic clues including leukocyturia (white blood cell casts or numerous white blood cells), bacteriuria, hematuria which may present as frank blood or microscopic hematuria, proteinuria, and occasionally pyuria with white blood cell casts specifically suggesting upper tract involvement[23][24]. Nitrites in urine suggest gram-negative bacteriuria and have modest specificity for bacterial infection though absence does not exclude infection[23]. The urine culture with quantitative bacterial colony counts remains the gold standard for microbiological diagnosis and ideally obtained prior to antibiotic initiation to preserve accuracy of organism identification and antimicrobial susceptibility determination[8][23]. Quantitative bacteriuria thresholds for diagnosis vary contextually based on collection method and host factors, with standards defining significant bacteriuria as greater than 100,000 colony-forming units per milliliter in asymptomatic patients, greater than 100 colony-forming units per milliliter of E. coli in symptomatic women, greater than 1,000 colony-forming units per milliliter in symptomatic men, any bacterial growth from suprapubic aspiration in any patient, or greater than 100 colony-forming units per milliliter in catheterized patients[1][24][7].

Blood cultures should be obtained in patients presenting with systemic toxicity, rigors, or clinical evidence of sepsis to assess for bacteremia which occurs in approximately 30 percent of acute pyelonephritis cases and carries prognostic significance for disease severity[46]. Serum chemistry evaluation assesses baseline renal function through measurement of serum creatinine and blood urea nitrogen to identify preexisting renal impairment and establish baseline values for monitoring. Procalcitonin elevation above 0.5 ng/mL represents an early and relatively specific marker of acute pyelonephritis with parenchymal involvement and may assist in risk stratification[58]. Complete blood count typically reveals leukocytosis with leftward shift reflecting the systemic inflammatory response, though normal white blood cell counts do not exclude pyelonephritis.

Imaging studies in uncomplicated acute pyelonephritis cases are not routinely necessary as clinical and laboratory findings typically suffice for diagnosis, but imaging becomes indicated when clinical response proves inadequate after 72 hours of appropriate antimicrobial therapy, when treatment failure is suspected, when complicated pyelonephritis is clinically suspected, or when anatomic abnormalities require exclusion[18][25]. Ultrasonography represents the initial imaging modality of choice for pyelonephritis evaluation due to its noninvasive nature, absence of ionizing radiation, ease of performance, and capacity to visualize kidney size, parenchymal echotexture abnormalities, caliceal dilatation suggesting obstruction, and presence of renal or perirenal collections suggesting abscess formation[18][20]. Renal ultrasound may demonstrate increased renal size with loss of corticomedullary differentiation, perinephric edema, or hypoechoic areas suggesting bacterial consolidation or nephritis[26].

Computed tomography with intravenous contrast provides superior resolution for identifying complications of pyelonephritis including renal and perirenal abscess formation, emphysematous changes, xanthogranulomatous transformation, or vascular complications, and achieves particular utility when diagnostic uncertainty persists or complicated infection is suspected[18][25][20]. Contrast-enhanced CT demonstrates characteristic findings of acute pyelonephritis including wedge-shaped or patchy areas of renal hypoperfusion in the arterial phase reflecting decreased blood flow to infected parenchyma, with relative hyperenhancement in delayed phases as contrast accumulates in the interstitium of affected areas[26]. Magnetic resonance imaging offers diagnostic value comparable to CT with advantages in pregnant patients where ionizing radiation exposure requires minimization, and demonstrates infected renal parenchyma as T1 hypointense, T2 hyperintense areas[26][49]. In pregnant women specifically, renal ultrasound and MRI without gadolinium remain preferred imaging approaches to minimize fetal radiation exposure[27][28].

Risk Factors and Predisposing Conditions

Multiple demographic, anatomic, and host-related factors substantially increase susceptibility to pyelonephritis development and influence disease severity and treatment response. Female gender represents perhaps the most prominent epidemiological risk factor across virtually all age groups reflecting reduced ureteral length facilitating bacterial ascension, altered periurethral flora, and sexual intercourse-associated traumatic inoculation of uropathogens into the lower urinary tract[1][3][5]. Sexual activity itself constitutes a recognized precipitant of acute pyelonephritis in young women, and use of spermicides or diaphragms as contraceptive methods increases infection risk through alteration of vaginal microbiota and facilitation of uropathogenic adherence[12][13]. New sexual partnership has been identified as a specific risk factor for infection initiation in young women, suggesting organism-specific immune status development through continued exposure to individual partner microbiota[12][13].

Diabetes mellitus represents a particularly significant metabolic risk factor for pyelonephritis, demonstrating substantially elevated infection incidence in diabetic women though paradoxically not demonstrating increased incidence in diabetic men; however, when diabetic patients of either gender acquire urinary tract infections, the infections characteristically present with increased severity and greater propensity for complications including renal abscess formation and sepsis[1][4][13]. The enhanced infection risk in diabetic patients reflects multiple contributory mechanisms including altered uroepithelial inflammatory response, elevated urinary glucose concentrations providing bacterial nutrients, neutrophil dysfunction impairing bacterial clearance, and increased asymptomatic bacteriuria prevalence[1][4]. The increased severity of infection in diabetics demands particularly aggressive treatment approaches and heightened vigilance for complications.

Pregnancy represents a distinctive physiologic state substantially increasing pyelonephritis risk, particularly during the second and third trimesters, with estimated pyelonephritis incidence during gestation of approximately 1 to 3 percent of pregnancies[27][28]. The pregnancy-associated altered urinary physiology including ureteral dilation (hydroureter) and decreased ureteral peristalsis attributable to progesterone effects combine with mechanical obstruction from the enlarging uterus to impede urine drainage and facilitate bacterial ascension[27][28]. Additionally, pregnant women demonstrate increased asymptomatic bacteriuria prevalence, with untreated bacteriuria progressing to acute pyelonephritis in approximately 20 to 40 percent of cases absent antimicrobial intervention; therefore, all pregnant women require systematic screening for bacteriuria and prompt treatment to prevent pyelonephritis development[27][28]. Pyelonephritis in pregnancy carries enhanced maternal morbidity risk and potential fetal consequences including preterm labor, intrauterine growth restriction, and perinatal mortality, necessitating particularly aggressive management.

Anatomic abnormalities of the urinary system represent paramount predisposing factors for pyelonephritis development and recurrence across age groups. Obstructive uropathy from any cause including renal calculi, ureteral strictures, ureteropelvic junction obstruction, or posterior urethral valves permits bacterial colonization and prevents mechanical clearance through urine flow, with obstructive uropathy representing the single most important risk factor enabling renal damage through infection and tissue destruction[1][4][20]. Vesicoureteral reflux allowing retrograde passage of urine from bladder to upper urinary tract substantially increases pyelonephritis risk particularly in children, with approximately 50 percent of children under age 2 years presenting with initial urinary tract infection demonstrating vesicoureteral reflux on voiding cystourethrography[1][4][14]. The presence of reflux dramatically elevates the risk of acute pyelonephritis and subsequent renal scarring, with high-grade reflux (grades IV-V) particularly conferring risk of permanent parenchymal damage[14][55].

Renal calculi represent additional mechanical risk factors, particularly struvite calculi composed of magnesium ammonium phosphate which form specifically in the context of urea-splitting bacterial infection and perpetuate infection once established; critically, infection will not resolve while infectious calculi remain in situ, necessitating calculus removal in addition to antibiotic therapy[1][4][20]. Polycystic kidney disease and other cystic renal disorders increase infection susceptibility through altered intrarenal architecture and altered urine flow dynamics. Neurogenic bladder from spinal cord injury, spina bifida, or other neuropathic conditions severely compromises normal urinary drainage and creates an environment favorable for repeated infections[1][4].

Indwelling urinary catheters whether suprapubic or transurethral constitute major risk factors for bacteriuria and pyelonephritis, with prolonged catheterization conferring substantially elevated infection risk through direct bacterial inoculation into the urinary system and biofilm formation on catheter surfaces conferring antibiotic resistance[1][3][18]. Immunosuppressive conditions including HIV/AIDS, chemotherapy-induced immunosuppression, hematologic malignancies, or immunosuppressive medications increase infection risk by impairing neutrophil function and T-lymphocyte-mediated immunity essential for bacterial containment[1][3][29].

Age-related factors profoundly influence pyelonephritis epidemiology, with elderly patients demonstrating elevated infection incidence partially attributable to benign prostatic hyperplasia in males causing urinary retention and incomplete emptying, postmenopausal estrogen depletion altering vaginal flora in females, and both genders experiencing age-related immune senescence with reduced capacity for infection containment[16][5][17]. Prior episodes of urinary tract infection including cystitis substantially increase risk of subsequent pyelonephritis, with recurrent infections conferring cumulative risk of progressive renal scarring particularly in younger populations where infection repetition over years produces substantial fibrotic changes[1][4][30].

Treatment Approaches Stratified by Disease Severity and Host Factors

The fundamental cornerstone of pyelonephritis management consists of antimicrobial therapy with selection of specific agents determined through integration of empiric coverage considerations, local resistance patterns, clinical severity, patient factors, and eventually microbiological culture results with susceptibility data[1][8][31]. The distinction between uncomplicated and complicated pyelonephritis substantially influences treatment route selection, antimicrobial agent choice, and duration of therapy, with uncomplicated cases in otherwise healthy individuals potentially amenable to careful outpatient oral therapy while complicated cases typically mandate hospitalization and intravenous antimicrobial administration.

Uncomplicated acute pyelonephritis in nonpregnant women demonstrating moderate clinical severity tolerating oral intake and capable of reliable outpatient follow-up may be treated with carefully selected oral antibiotics administered for 14 days with high cure rates approaching 90 to 95 percent achieved with appropriate agent selection[32][9][33]. Preferred oral antimicrobial agents for uncomplicated female pyelonephritis include amoxicillin-clavulanate administered as 500 mg of amoxicillin with 125 mg of clavulanate three times daily, second- or third-generation cephalosporins such as cefuroxime axetil 250 mg twice daily or cefixime 400 mg daily, or fluoroquinolones including norfloxacin 400 mg twice daily or ciprofloxacin 500 mg twice daily, all administered for 14-day courses[32][9][33]. Alternative agents include fluoroquinolones which achieve good renal penetration and excellent oral bioavailability though fluoroquinolone use requires judicious restriction given escalating resistance patterns globally[32]. Fosfomycin trometamol as a single 3-gram dose achieves approximately 90 percent cure rates in uncomplicated cystitis but data specifically supporting its use in pyelonephritis remain more limited[9][28].

Moderate to severe uncomplicated pyelonephritis or cases with potential treatment compliance concerns necessitate hospitalization with intravenous antimicrobial therapy, with preferred first-line parenteral agents including ceftriaxone 1 gram daily or amoxicillin-clavulanate 1 gram intravenously every 8 hours[9][34][48]. For patients manifesting beta-lactam allergy, fluoroquinolone options include ciprofloxacin or ofloxacin, though emerging resistance particularly among Klebsiella and other gram-negatives increasingly limits quinolone utility for empiric therapy[32][34][21]. Aztreonam administered at 1 gram intravenously every 8 hours represents an alternative for severely penicillin-allergic patients without cross-reactivity to other beta-lactams[34][27]. For suspected multidrug-resistant gram-negative pathogens, ertapenem, piperacillin-tazobactam, or newer agents including aztreonam-avibactam provide activity against extended-spectrum beta-lactamase and carbapenemase-producing organisms[47].

Once clinical improvement manifests, typically within 48 to 72 hours of appropriate therapy, transition to oral antimicrobial continuation therapy may proceed with completion of a total 14-day course[8][9][34]. Some patients achieve adequate clinical response permitting discharge with initial parenteral dose followed by extended oral therapy, though many require several days of continued inpatient hospitalization and intravenous therapy for clinical stabilization.

Complicated pyelonephritis invariably requires hospitalization with empiric intravenous antimicrobial therapy adjusted based on suspected pathogenic organisms accounting for local resistance patterns[31][9][34][48]. Imaging studies including ultrasonography or computed tomography become routinely indicated in complicated cases to exclude obstructive uropathy, renal or perirenal abscess formation, emphysematous pyelonephritis, or xanthogranulomatous infection requiring specific therapeutic interventions beyond antibiotics[31][18][34]. Should imaging reveal obstructive uropathy, urgent decompression through percutaneous nephrostomy tube placement or retrograde ureteral stent insertion becomes necessary as antibiotics alone cannot penetrate adequately into obstructed, infected renal parenchyma, creating conditions favoring therapeutic failure and progressive renal destruction[31][34][52].

Renal or perirenal abscess formation complicating pyelonephritis represents a severe manifestation with mortality rates of 1.5 to 15 percent historically, though contemporary reports suggest improved outcomes through combined intensive antibiotic therapy with radiologically guided percutaneous drainage rather than mandatory surgical approaches[49]``[52]. Microabscesses frequently resolve with medical management alone during prolonged antibiotic therapy lasting 4 to 6 weeks, whereas larger abscess collections typically require percutaneous catheter drainage under imaging guidance to achieve adequate source control[49]``[52]. Emphysematous pyelonephritis—a necrotizing infection characterized by gas formation within renal parenchyma predominantly in diabetic patients—represents a medical emergency requiring immediate antibiotic therapy combined with urgent surgical drainage or nephrectomy, with historically poor prognosis though selected cases managed with aggressive medical therapy achieve survival[52].

Pregnant women presenting with pyelonephritis require hospitalization with intravenous antimicrobial therapy administered for 10 to 14 days followed by transition to oral therapy to complete treatment, with antibiotic selection restricted to agents safe during pregnancy[27][28]. First-line empiric agents for pregnant women include ampicillin 2 grams intravenously every 8 hours combined with gentamicin 3 to 5 mg/kg intravenously daily, or alternatively ceftriaxone 1 gram intravenously daily or cefuroxime axetil 750 mg intravenously every 8 hours[27][28]. Fluoroquinolones are contraindicated in pregnancy due to teratogenic concerns and tendon abnormalities in animal models, as is nitrofurantoín during the third trimester and near delivery due to risk of hemolytic anemia in neonates[27]. Following completion of acute pyelonephritis treatment, pregnant women warrant either suppressive therapy with daily low-dose antibiotics (cefalexin 250-500 mg daily or nitrofurantoín 100 mg daily when not contraindicated) continuing through gestation and 4 to 6 weeks postpartum, or alternatively close surveillance with repeat urine cultures monthly to detect recurrent infection promptly[27][28].

Pediatric pyelonephritis management depends substantially on age, severity, underlying anomalies, and presence of vesicoureteral reflux or other urostructural abnormalities[14][15][35]. Very young infants under 3 months of age generally warrant hospital admission with intravenous antibiotics given substantially elevated risk of bacteremia and potential for rapidly progressive sepsis in this immunologically immature population[14][15][35]. Older infants and children demonstrating uncomplicated pyelonephritis with good clinical status and reliable follow-up potential may receive initial parenteral dose followed by oral continuation therapy in the ambulatory setting, though many practitioners prefer inpatient management for at least initial days of therapy[14][15][35]. Preferred agents in pediatrics include ampicillin combined with gentamicin or third-generation cephalosporins such as ceftriaxone for initial parenteral therapy, with transition to oral agents including amoxicillin-clavulanate, cephalexin, or cefixime for continued ambulatory therapy[14][15].

Elderly patients with pyelonephritis warrant hospitalization given increased likelihood of complicated disease, underlying comorbidities including diabetes and chronic kidney disease, potential for rapid progression to sepsis and multiorgan failure, and frequent presentation with atypical symptoms delaying diagnosis[17][36]. Empiric antimicrobial coverage should account for likely pathogenic organisms with consideration of regional resistance patterns and patient-specific factors including renal function necessitating dosage adjustment of aminoglycosides and other renally-cleared agents[17].

Supportive care measures constitute essential adjunctive components of pyelonephritis management including aggressive intravenous hydration to maintain adequate intravascular volume, urine output, and promotion of bacterial clearance, fever management with antipyretics, pain control with analgesics including nonsteroidal anti-inflammatory agents or acetaminophen for milder pain or opioid analgesics for severe discomfort, and bed rest to optimize body's resource allocation to immune responses. Antiemetic medications alleviate nausea and vomiting facilitating adequate oral hydration and medication intake in patients managed ambulatorially or transitioned to oral therapy.

Prevention Strategies and Risk Reduction

Prevention of pyelonephritis requires multifaceted approaches targeting identified modifiable risk factors and host factors amenable to intervention. General population measures applicable to both genders include maintaining adequate daily hydration particularly with water intake, which promotes frequent urination and mechanical flushing of uropathogens from the lower urinary tract prior to ascension[8][12]. Most healthy adults should target consumption of 6 to 8 glasses of 8-ounce water servings daily, though individuals with underlying renal disease, heart failure, or bladder dysfunction require individualized fluid prescription[8].

Female-specific preventive strategies focus on reduction of bacterial translocation and contamination including proper perineal hygiene with cleaning directed from anterior to posterior (front to back) after urination and defecation to prevent colonic flora from spreading toward the urethra[8][12]. Regular urination at intervals of every 3 to 4 hours minimizes bacterial proliferation in bladder urine that remains static for prolonged intervals[8][12]. Micturition immediately following coitus removes bacteria potentially introduced during sexual intercourse, substantially reducing subsequent infection risk[8][12][13]. Avoidance of vaginal irritants including douches, feminine hygiene sprays, and scented products reduces disruption of protective vaginal microbiota; selection of cotton underwear over synthetic fibers permits improved moisture evaporation reducing warm moist environments favorable for bacterial proliferation[8][12][13]. Women utilizing spermicides or diaphragms as contraceptive methods experience elevated infection risk and may benefit from alternative contraceptive selection when feasible[1][12][13].

Pregnant women warrant particular preventive attention with systematic screening for asymptomatic bacteriuria through urine culture at initial prenatal evaluation, as untreated bacteriuria carries 20 to 40 percent risk of progression to symptomatic pyelonephritis particularly during later pregnancy[27][28]. Any pregnant woman with positive urine culture should receive appropriate antimicrobial therapy followed by monthly surveillance urine cultures to detect recurrent infection prompting re-treatment[27][28]. Suppressive antimicrobial therapy administered to pregnant women with prior pyelonephritis episodes or recurrent infections continues throughout gestation preventing recurrence[27][28].

Patients with anatomic risk factors including urinary calculi, vesicoureteral reflux, obstruction, or neurogenic bladder require specialized preventive approaches including antimicrobial suppression, correction of structural abnormalities when feasible, and close surveillance for infection development. Patients with recurrent urinary tract infections not explained by identified structural abnormalities may benefit from individualized antimicrobial suppression with continuous low-dose daily antibiotics or postcoital antimicrobial dosing when infections correlate temporally with sexual intercourse, though long-term suppression requires careful risk-benefit assessment given development of antimicrobial resistance[6][29].

Emerging evidence suggests cranberry extracts containing proanthocyanidins may reduce bacterial adherence to uroepithelial surfaces, though clinical trials demonstrate inconsistent efficacy and side effects; thus cranberry cannot substitute for proven prevention measures[53]. Similarly, probiotics including Lactobacillus species may provide modest benefit in recurrent infection prevention through alteration of vaginal flora, though evidence remains preliminary[53].

Complications and Long-term Consequences

When pyelonephritis remains untreated or inadequately treated, multiple serious complications may develop ranging from immediate life-threatening conditions to chronic progressive renal dysfunction. Sepsis represents the most immediately life-threatening complication, occurring when bacterial infection and associated inflammatory mediators progress beyond localized renal involvement to cause systemic inflammatory response manifesting as fever, tachycardia, tachypnea, hypotension, and in severe cases septic shock with multiorgan failure[10][37][11]. Sepsis development in the context of pyelonephritis carries substantial mortality particularly in elderly and immunocompromised populations, necessitating recognition and aggressive management[10][37]. Renal and perirenal abscess formation represents an additional severe acute complication manifesting as localized suppurative collections within renal parenchyma or surrounding perirenal space, presenting with persistent fever despite appropriate antibiotic therapy, and typically requiring percutaneous drainage beyond antimicrobial therapy alone[10][49]``[52].

Emphysematous pyelonephritis represents a rare but severe necrotizing infection characterized by gas formation within renal parenchyma and collecting system, occurring predominately in diabetic patients and representing a medical emergency requiring immediate antibiotics combined with urgent surgical intervention[10][52]. Xanthogranulomatous pyelonephritis, an even rarer chronic destructive infection, develops in the context of chronic obstruction and recurrent infection with characteristic histological replacement of normal renal tissue with foamy lipid-laden macrophages, frequently requiring nephrectomy[6][57].

Chronic renal scarring represents the most prevalent long-term sequel of pyelonephritis, particularly when infection occurs during infancy and early childhood when renal parenchyma remains developmentally vulnerable[10][11][51]. Acute pyelonephritis inciting episodes result in renal scar formation in approximately 40 to 50 percent of affected children by 6 months following initial infection, with scars persisting indefinitely causing permanent functional impairment of affected renal tissue[54]. Renal scarring reduces glomerular filtration capacity of affected parenchyma, and multiple scars or bilateral involvement creates cumulative functional loss potentially progressing to chronic kidney disease[10][30][11][51]. Scarring particularly affects cortical parenchyma with characteristic retraction of calices and cortical thinning visible on imaging studies, and represents irreversible pathology as no current therapeutic intervention restores scarred tissue function[10][30][51].

Hypertension develops in substantial proportions of patients experiencing recurrent pyelonephritis with renal scarring, particularly when scarring involves both kidneys, through mechanisms involving renin-angiotensin system activation from areas of renal hypoperfusion and reduced glomerular filtration[10][11][51]. Proteinuria frequently accompanies renal scarring reflecting altered glomerular architecture and filtration barrier dysfunction, with proteinuria amplitude correlating with extent of parenchymal damage[10][11]. Chronic kidney disease progressing to end-stage renal failure requiring dialysis develops in patients experiencing extensive bilateral scarring or recurrent infections compromising the cumulative functional renal mass[10][37][11]. These progressive renal consequences necessitate long-term nephrology surveillance monitoring renal function, blood pressure, proteinuria, and electrolyte status in patients with documented pyelonephritis history.

The risk of permanent renal scarring escalates dramatically in the presence of specific pathologic features including vesicoureteral reflux of high grade, particularly grades IV and V, young age at infection onset particularly under 5 years of age, delayed treatment institution, recurrent infection episodes, and presence of underlying urostructural abnormalities[1][4][14][51]``[54]``[55]. Children demonstrating pyelonephritis with high-grade vesicoureteral reflux require particularly aggressive management and close follow-up surveillance given substantially elevated scarring risk[14][55]. The association between recurrent pyelonephritis and progressive renal failure in pediatric populations necessitates meticulous preventive efforts including early infection treatment, investigation for underlying anatomic abnormalities, antimicrobial suppression when indicated, and serial imaging assessment to detect scarring development.

Conclusion and Clinical Synthesis

Pyelonephritis represents a substantial clinical challenge affecting millions globally with diverse presentation patterns, complex etiologic factors, and serious potential for both acute complications and chronic sequelae demanding prompt recognition and appropriate therapeutic intervention. The disease overwhelmingly affects women across most age groups while demonstrating characteristic epidemiologic variations in pediatric and elderly populations warranting age-specific diagnostic and management approaches. Causative pathogens remain predominantly Escherichia coli in uncomplicated community-acquired infections though multidrug-resistant organisms increasingly complicate nosocomial and complicated cases necessitating antimicrobial stewardship informed by local resistance patterns and culture-directed narrowing of initial empiric coverage. Clinical recognition depends upon maintaining appropriate diagnostic suspicion particularly in atypical presentations encountered in pediatric and geriatric populations where symptoms diverge substantially from classic adult presentations.

Management stratification based on disease complexity and patient factors optimizes outcomes through calibrated antimicrobial selection, appropriate route of administration, and targeted duration of therapy. Uncomplicated pyelonephritis in selected healthy individuals may receive careful outpatient oral management, while complicated presentations invariably require hospitalization and parenteral therapy with adjunctive imaging investigation and intervention for obstructive uropathy or abscess formation as clinically indicated. Pregnant women require specialized management incorporating antimicrobial agents safe in gestation and suppressive strategies preventing recurrence and associated fetal complications.

Prevention through behavioral modification, reduction of modifiable risk factors, and systematic screening in high-risk populations substantially reduces disease incidence and its chronic consequences. Prompt treatment of initial episodes minimizes risk of progression to chronic pyelonephritis with associated permanent renal scarring, particularly through vigilant investigation for underlying anatomic abnormalities permitting corrective intervention. Long-term follow-up of patients with pyelonephritis history remains essential to detect progressive renal functional decline and associated hypertension requiring management to minimize progression to end-stage renal disease. Future efforts toward antimicrobial stewardship, development of novel therapeutic approaches for multidrug-resistant organisms, and identification of interventions to prevent renal scarring will further improve outcomes in this prevalent infectious disease.

Fuentes

  1. https://www.cun.es/enfermedades-tratamientos/enfermedades/pielonefritis
  2. https://www.niddk.nih.gov/health-information/informacion-de-la-salud/enfermedades-urologicas/infeccion-renal-pielonefritis
  3. https://colombianadetrasplantes.com/web/enfermedad-renal/que-es-pielonefritis-y-como-prevenirla/
  4. https://www.saludsavia.com/contenidos-salud/enfermedades/pielonefritis
  5. https://www.fesemi.org/informacion-pacientes/conozca-mejor-su-enfermedad/pielonefritis
  6. https://www.huvn.es/archivos/cms/ginecologia-y-obstetricia/archivos/publico/Protocolos_clinicos/Embarazo/Patolog%C3%ADa%20urinaria%20en%20la%20gestaci%C3%B3n.pdf
  7. http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0211-69952009000500022
  8. https://www.niddk.nih.gov/health-information/informacion-de-la-salud/enfermedades-urologicas/infeccion-renal-pielonefritis/tratamiento
  9. https://manualclinico.hospitaluvrocio.es/urgencias/e-infecciosas/pielonefritis-aguda-infeccion-del-tracto-urinario/
  10. https://www.clinicauandes.cl/noticia/pielonefritis-principal-complicacion-de-una-infeccion-urinaria
  11. https://www.msdmanuals.com/es/professional/ginecolog%C3%ADa-y-obstetricia/abordaje-de-la-mujer-embarazada-y-atenci%C3%B3n-prenatal/infecciones-urinarias-en-el-embarazo
  12. https://www.pediatriaintegral.es/publicacion-2022-12/infeccion-del-tracto-urinario-y-reflujo-vesicoureteral/
  13. https://www.msdmanuals.com/es/hogar/trastornos-renales-y-del-tracto-urinario/infecciones-urinarias-iu/bacteriuria-asintom%C3%A1tica
  14. https://www.doctoralia.es/preguntas-respuestas/cuanto-duran-los-sintomas-de-pielonefritis-hoy-termine-el-tratamiento-con-ciprofloxacina-500mg-cad
  15. https://dialnet.unirioja.es/descarga/articulo/10082406.pdf
  16. https://www.niddk.nih.gov/health-information/informacion-de-la-salud/enfermedades-urologicas/infeccion-renal-pielonefritis/sintomas-causas
  17. https://www.misistemainmune.es/enfermedades-sistema-inmunitario/infecciosas/prevenir-y-tratar-las-infecciones-urinarias-recurrentes
  18. https://aeuexp.aeu.es/areas-de-experiencia/vejiga/infeccion-urinaria-itu/pielonefritis/
  19. https://www.pfizer.es/noticias/noticias-2025/disponible-en-espa%C3%B1a-el-nuevo-tratamiento-de-pfizer-frente-a-infecciones-multirresistentes-con-opciones-terap%C3%A9uticas-limitadas
  20. https://empendium.com/manualmibe/compendio/chapter/B34.II.14.8.11.5.
  21. https://www.mayoclinic.org/es/diseases-conditions/hydronephrosis/symptoms-causes/syc-20575276
  22. https://www.qida.es/blog/infeccion-de-orina-en-personas-mayores
  23. https://sanidad.castillalamancha.es/sites/sescam.castillalamancha.es/files/documentos/farmacia/v_1_fluoroquinolonas.pdf
  24. https://vithas.es/consejo/como-prevenir-una-pielonefritis/
  25. https://www.cun.es/diccionario-medico/terminos/cicatriz-renal
  26. https://www.msdmanuals.com/es/professional/trastornos-urogenitales/infecciones-urinarias/pielonefritis-cr%C3%B3nica
  27. https://www.deflux.com/es_US/my-child-has-vur/the-vur-terms-you-will-hear/what-parents-should-know-about-pediatric-pyelonephritis/
  28. https://www.sanitas.es/biblioteca-de-salud/enfermedades-y-trastornos/urologicas/pielonefritis
  29. https://analesdepediatria.org/es-cicatrices-renales-menores-36-meses-articulo-S1695403316300066
  30. https://www.quironsalud.com/ruber-internacional/es/comunicacion/patologias/pielonefritis
  31. https://www.guiaprioam.com/indice/pielonefritis-aguda/
  32. https://www.sergas.es/Docs/ProtInfUriAdulto.pdf
  33. https://urologoenvigo.com/enfermedades-del-rinon/pielonefritis-aguda/
  34. https://www.youtube.com/watch?v=f7_XyRoxB_0
  35. https://www.revistasam.com.ar/index.php/RAM/article/view/1117
  36. https://medlineplus.gov/spanish/ency/article/000506.htm
  37. https://www.niddk.nih.gov/health-information/informacion-de-la-salud/enfermedades-urologicas/infeccion-renal-pielonefritis/diagnostico
  38. https://www.barnaclinic.com/blog/urologia/pielonefritis-que-es-causas-tratamiento/
  39. https://cinfasalud.cinfa.com/p/pielonefritis/
  40. https://www.hospitalaustral.edu.ar/wp-content/uploads/2020/05/pautas-de-alarma-pielonefritis.pdf
  41. https://www.msdmanuals.com/es-es/hogar/trastornos-renales-y-del-tracto-urinario/infecciones-urinarias-iu/infecci%C3%B3n-renal
  42. https://www.boucomayores.es/blog/infeccion-orina-personas-mayores/
  43. https://www.resistenciaantibioticos.es/sites/default/files/biblioteca-universidades/08_caso-clinico-pielonefritis.pdf
  44. https://analesdepediatria.org/es-criterios-ingreso-hospitalario-las-infecciones-articulo-13111600
  45. https://www.healthychildren.org/Spanish/health-issues/conditions/genitourinary-tract/Paginas/Vesicoureteral-Reflux-in-Infants-Young-Children.aspx

Respuesta generada por inteligencia artificial a partir de las fuentes citadas. Verifica las fuentes antes de aplicarla.

¿Tienes una pregunta sobre tu propio caso? Itaca responde con fuentes en segundos.

Hacer una pregunta

Más preguntas sobre pielonefritis